278.48
-6.18 (-2.17%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bearish | Bullish |
Stockmoo Score
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Paulson & Co. Inc. | 31 Mar 2024 | 1,775,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 385.00 (JMP Securities, 38.25%) | Buy |
| Median | 371.00 (33.22%) | |
| Low | 360.00 (Evercore ISI Group, 29.27%) | Buy |
| Average | 372.00 (33.58%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 253.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 08 Aug 2024 | 371.00 (33.22%) | Buy | 243.64 |
| Evercore ISI Group | 08 Aug 2024 | 360.00 (29.27%) | Buy | 243.64 |
| JMP Securities | 16 Jul 2024 | 385.00 (38.25%) | Buy | 273.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Aug 2024 | Announcement | Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
| 07 Aug 2024 | Announcement | Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates |
| 02 Aug 2024 | Announcement | Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel |
| 24 Jul 2024 | Announcement | Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |